REVIEW article
Front. Physiol.
Sec. Vascular Physiology
Volume 16 - 2025 | doi: 10.3389/fphys.2025.1674714
This article is part of the Research TopicInsights in Vascular Physiology: 2025View all 4 articles
Hippo in smooth muscle - a therapeutic target in vascular diseases driven by aging and hypertension
Provisionally accepted- 1Department of Experimental Medical Science, Lund University, Lund, Sweden
- 2Vascular Biology Group, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: The Hippo signaling pathway is a key regulator of cellular growth and organ size, acting through the transcriptional coactivators YAP and TAZ. These proteins shuttle between the nucleus and cytoplasm in response to Hippo pathway activity, which, when active, leads to cytoplasmic sequestration and degradation of YAP/TAZ, preventing them from initiating gene transcription. Although initially studied in development and cancer, recent research has revealed crucial functions for YAP and TAZ in the adult vascular wall. Scope of the Review: This review discusses emerging insights into the roles of Hippo signaling and its downstream effectors YAP and TAZ in adult vascular smooth muscle cells (SMCs) and endothelial cells (ECs), with an emphasis on their physiological and pathological relevance. Key Findings: In SMCs, YAP and TAZ are vital for maintaining contractile identity by regulating expression of SMC contractile proteins. Inducible deletion of YAP/TAZ in adult SMCs results in impaired contractility, hypotension, and spontaneous arterial aneurysms. Despite these findings, the role of upstream Hippo signaling in SMCs remains poorly understood, and its therapeutic potential is underexplored. In ECs, YAP and TAZ respond to disturbed flow patterns by promoting a pro-atherogenic gene expression profile, contributing to increased atherosclerotic burden in hypercholesterolemic conditions. Discussion and Conclusion: Targeting Hippo-YAP/TAZ signaling in vascular cells represents a promising yet complex strategy for treating vascular diseases. The key challenge lies in achieving precise, cell-specific, and temporally controlled modulation that enhances beneficial effects, such as aneurysm protection and arterial repair, while minimizing off-target or adverse effects in non-vascular tissues.
Keywords: Hippo, YAP, TAZ, Myocardin, Smooth muscle, Aneurysm, Atherosclerosis, Lats2
Received: 28 Jul 2025; Accepted: 19 Sep 2025.
Copyright: © 2025 Albinsson, Rippe, Daoud, Bastrup, Holmberg, Jepps and Swärd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Karl Henrik Swärd, karl.sward@med.lu.se
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.